Real-world effectiveness and safety of first-line bevacizumab (BEV) plus paclitaxel (PAC) in > 2000 patients (pts) with HER2-negative metastatic breast cancer (mBC)

被引：2

作者：

Mueller, V. ^{[1
]}

Dank, M. ^{[2
]}

de Ducla, S. ^{[3
]}

Mitchell, L. ^{[4
]}

Schneeweiss, A. ^{[5
]}

机构：

[1] Univ Med Ctr Hamburg Eppendorf, Dept Gynecol, Hamburg, Germany

[2] Semmelweis Univ, Ctr Canc, Div Oncol, Budapest, Hungary

[3] F Hoffmann La Roche Ltd, Pharma Dev Med Affairs, Basel, Switzerland

[4] F Hoffmann La Roche Ltd, Pharma Dev Med Affairs Biometr, Basel, Switzerland

[5] Univ Heidelberg Hosp, Natl Ctr Tumor Dis, Div Gynecol Oncol, Heidelberg, Germany

来源：

关键词：

D O I：

10.1093/annonc/mdw365.16

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

237P

引用

页数：1

Real-world effectiveness and safety of first-line bevacizumab (BEV) plus paclitaxel (PAC) in &gt; 2000 patients (pts) with HER2-negative metastatic breast cancer (mBC)